Covered recipient · General Payments record
BRUCE RASHBAUM
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$81,160.23
200 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $57,670.00 | 22 |
| Travel and Lodging | $14,889.67 | 29 |
| Consulting Fee | $4,510.00 | 1 |
| Food and Beverage | $4,086.68 | 147 |
| Education | $3.88 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $63,333.56 | 92 |
| Janssen Products, LP | $15,971.80 | 20 |
| Janssen Biotech, Inc. | $604.70 | 23 |
| Theratechnologies Inc. | $254.33 | 11 |
| Merck Sharp & Dohme Corporation | $169.94 | 13 |
| Amgen Inc. | $162.50 | 4 |
| Kowa Pharmaceuticals America, Inc. | $118.61 | 7 |
| Napo Pharmaceuticals Inc | $65.62 | 4 |
| Novo Nordisk Inc | $59.33 | 3 |
| Mylan Institutional Inc. | $55.65 | 3 |
| Takeda Pharmaceuticals U.S.A., Inc. | $51.85 | 3 |
| AbbVie, Inc. | $51.80 | 3 |
| ViiV Healthcare Company | $47.52 | 2 |
| Endo Pharmaceuticals Inc. | $40.02 | 2 |
| ARBOR PHARMACEUTICALS, INC. | $28.99 | 2 |
| AstraZeneca Pharmaceuticals LP | $24.20 | 1 |
| Regeneron Healthcare Solutions, Inc. | $21.81 | 1 |
| Mylan Pharmaceuticals Inc. | $20.41 | 1 |
| SANOFI PASTEUR INC. | $19.30 | 1 |
| PFIZER INC. | $16.43 | 1 |
| Aytu BioScience, Inc | $15.16 | 1 |
| Adlon Therapeutics L.P. | $14.16 | 1 |
| Lilly USA, LLC | $12.54 | 1 |
Page 4 of 4; records 151–200 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BRUCE RASHBAUM
NPI 1568555456 · CMS profile ID 298002
Allopathic & Osteopathic Physicians / Internal Medicine
WASHINGTON, DC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 4; records 151–200 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1568555456?year=2019&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BRUCE RASHBAUM, NPI 1568555456, CMS profile ID 298002. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–200 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568555456?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). BRUCE RASHBAUM, NPI 1568555456, CMS profile ID 298002. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–200 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568555456?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- BRUCE RASHBAUM, NPI 1568555456, CMS profile ID 298002, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–200 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1568555456?year=2019&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
200 matching records · $81,160.23 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 200.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Products, LP | $2,500.00 | 03/22/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657616379 | CMS |
| Gilead Sciences, Inc. | $17.56 | 03/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681589541 | CMS |
| Mylan Institutional Inc. | $19.39 | 03/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 701641137 | CMS |
| Janssen Biotech, Inc. | $19.55 | 03/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658663031 | CMS |
| Janssen Biotech, Inc. | $17.09 | 03/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658663027 | CMS |
| Janssen Products, LP | $405.70 | 03/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657616377 | CMS |
| SANOFI PASTEUR INC. | $19.30 | 03/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691640543 | CMS |
| Janssen Products, LP | $2,500.00 | 03/13/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657616375 | CMS |
| Gilead Sciences, Inc. | $30.93 | 03/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681589539 | CMS |
| Theratechnologies Inc. | $32.15 | 03/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703941775 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $13.18 | 03/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681985223 | CMS |
| Novo Nordisk Inc | $21.55 | 03/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 669499133 | CMS |
| Janssen Biotech, Inc. | $21.75 | 03/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658663023 | CMS |
| Lilly USA, LLC | $12.54 | 03/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657720561 | CMS |
| Amgen Inc. | $17.43 | 02/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662228793 | CMS |
| Janssen Biotech, Inc. | $31.86 | 02/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658663019 | CMS |
| Janssen Products, LP | $405.70 | 02/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657616373 | CMS |
| Gilead Sciences, Inc. | $30.45 | 02/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681589537 | CMS |
| Gilead Sciences, Inc. | $17.11 | 02/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681589535 | CMS |
| Merck Sharp & Dohme Corporation | $16.62 | 02/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695651775 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $22.41 | 02/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681999229 | CMS |
| Gilead Sciences, Inc. | $7.40 | 02/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681589531 | CMS |
| Gilead Sciences, Inc. | $25.00 | 02/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681589533 | CMS |
| Amgen Inc. | $9.93 | 02/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662228791 | CMS |
| Gilead Sciences, Inc. | $24.46 | 02/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681589529 | CMS |
| Janssen Biotech, Inc. | $32.33 | 02/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658663017 | CMS |
| Mylan Institutional Inc. | $17.89 | 02/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 701641133 | CMS |
| Novo Nordisk Inc | $22.56 | 02/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 668785795 | CMS |
| Gilead Sciences, Inc. | $1,715.00 | 02/06/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679316269 | CMS |
| Gilead Sciences, Inc. | $3,180.00 | 02/06/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679316273 | CMS |
| Theratechnologies Inc. | $21.02 | 02/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703941773 | CMS |
| Gilead Sciences, Inc. | $15.00 | 02/04/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679353443 | CMS |
| Gilead Sciences, Inc. | $209.94 | 02/04/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679353445 | CMS |
| Gilead Sciences, Inc. | $640.99 | 02/04/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679353449 | CMS |
| Gilead Sciences, Inc. | $641.38 | 02/04/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679353453 | CMS |
| Gilead Sciences, Inc. | $29.86 | 02/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681589527 | CMS |
| Janssen Biotech, Inc. | $23.64 | 02/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658663013 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $16.26 | 01/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 682052807 | CMS |
| Merck Sharp & Dohme Corporation | $15.65 | 01/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695646043 | CMS |
| Gilead Sciences, Inc. | $2,450.00 | 01/24/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679316263 | CMS |
| Gilead Sciences, Inc. | $32.18 | 01/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681589525 | CMS |
| Gilead Sciences, Inc. | $106.69 | 01/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681589523 | CMS |
| Theratechnologies Inc. | $22.04 | 01/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703941771 | CMS |
| Janssen Products, LP | $2,500.00 | 01/18/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657616371 | CMS |
| Janssen Biotech, Inc. | $33.15 | 01/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658663007 | CMS |
| Napo Pharmaceuticals Inc | $21.20 | 01/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 702236381 | CMS |
| Janssen Products, LP | $408.20 | 01/14/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657616369 | CMS |
| Gilead Sciences, Inc. | $17.90 | 01/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681589521 | CMS |
| ARBOR PHARMACEUTICALS, INC. | $14.05 | 01/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697369109 | CMS |
| Amgen Inc. | $12.93 | 01/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662228789 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021
- Generated from
- OP_DTL_GNRL_PGYR2021_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2019 | Principal investigator | $179,204.11 | 26 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
26 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Gilead Sciences, Inc. | $403.00 | 11/06/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection | No dispute reported | 06/30/2026 | 676381483 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,418.55 | 09/04/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection | No dispute reported | 06/30/2026 | 676381473 |
| Principal investigator 1 | Gilead Sciences, Inc. | $505.00 | 08/21/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults | No dispute reported | 06/30/2026 | 676381449 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,378.00 | 08/21/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects | No dispute reported | 06/30/2026 | 676381455 |
| Principal investigator 1 | Gilead Sciences, Inc. | $13,761.00 | 08/21/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection | No dispute reported | 06/30/2026 | 676381465 |
| Principal investigator 1 | Gilead Sciences, Inc. | $955.00 | 07/17/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects | No dispute reported | 06/30/2026 | 676381419 |
| Principal investigator 1 | Gilead Sciences, Inc. | $970.00 | 07/17/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults | No dispute reported | 06/30/2026 | 676381426 |
| Principal investigator 1 | Gilead Sciences, Inc. | $14,340.00 | 07/17/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection | No dispute reported | 06/30/2026 | 676381439 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,100.00 | 06/19/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects | No dispute reported | 06/30/2026 | 676381398 |
| Principal investigator 1 | Gilead Sciences, Inc. | $21,510.00 | 06/19/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection | No dispute reported | 06/30/2026 | 676381407 |
| Principal investigator 1 | Gilead Sciences, Inc. | $286.20 | 06/12/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection | No dispute reported | 06/30/2026 | 676381391 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,768.00 | 05/22/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects | No dispute reported | 06/30/2026 | 676381371 |
| Principal investigator 1 | Gilead Sciences, Inc. | $14,340.00 | 05/22/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection | No dispute reported | 06/30/2026 | 676381381 |
| Principal investigator 1 | Gilead Sciences, Inc. | $649.00 | 04/17/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults | No dispute reported | 06/30/2026 | 676381345 |
| Principal investigator 1 | Gilead Sciences, Inc. | $955.00 | 04/17/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects | No dispute reported | 06/30/2026 | 676381351 |
| Principal investigator 1 | Gilead Sciences, Inc. | $22,796.00 | 04/17/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection | No dispute reported | 06/30/2026 | 676381361 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,780.36 | 04/15/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection | No dispute reported | 06/30/2026 | 676381339 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,423.00 | 03/20/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects | No dispute reported | 06/30/2026 | 676381325 |
| Principal investigator 1 | Gilead Sciences, Inc. | $14,522.00 | 03/20/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection | No dispute reported | 06/30/2026 | 676381333 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,512.00 | 02/21/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES PC | A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor Combined With Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically-suppressed, Human Immunodeficiency Virus Type 1 Infected Subjects | No dispute reported | 06/30/2026 | 654245081 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,955.00 | 02/20/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects | No dispute reported | 06/30/2026 | 676381308 |
| Principal investigator 1 | Gilead Sciences, Inc. | $13,418.00 | 02/20/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection | No dispute reported | 06/30/2026 | 676381317 |
| Principal investigator 1 | Gilead Sciences, Inc. | $999.00 | 01/28/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults | No dispute reported | 06/30/2026 | 676381284 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,777.00 | 01/28/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects | No dispute reported | 06/30/2026 | 676381293 |
| Principal investigator 1 | Gilead Sciences, Inc. | $29,317.00 | 01/28/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES, PC | A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection | No dispute reported | 06/30/2026 | 676381301 |
| Principal investigator 1 | Janssen Research & Development, LLC | $366.00 | 01/28/2019 | Non-covered Recipient Entity CAPITAL MEDICAL ASSOCIATES PC | A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once Daily Fixed Dose Combination Regimen Versus a Regimen Consisting of Darunavir/Cobicistat Fixed Dose Combination Coadministered With Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 Infected Subjects | No dispute reported | 06/30/2026 | 654245079 |